Age: 58 Chairman Since 2014 Ph.D
The company has return on total asset (ROA) of 6.47 % which means that it generated profit of $6.47 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 12.69 % meaning that it created $12.69 on every $100 dollars invested by stockholders.
The company currently holds 52.72 M in liabilities with Debt to Equity (D/E) ratio of 0.91 which is about average as compared to similar companies. Sucampo Pharmaceuticals Inc has Current Ratio of 2.61 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Sucampo price boundaries
Entity SummarySucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. Sucampo Pharmaceuticals Inc [SCMP] is traded on NASDAQ General Markets in USA. It is located in Sucampo Pharmaceuticals, Inc.Bethesda, MD and employs 128 people.
Filter other executives
Sucampo Pharmaceuticals IncUSA StockCurrency: USD - US DollarTraded on NASDAQ General Markets
Fix Your Portfolios with Sucampo
Promote Sucampo and Ryuji Ueno
Sucampo Pharmaceuticals Leadership
Use alpha and beta coefficients to find investment opportunities after accounting for the riskFind Alpha
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and familiesResearch Equities
Find insiders across different sectors to evaluate their impact on performance and growth of their entitiesResearch Insiders